The AP3B1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa cell line, designed for the disruption of the AP3B1 gene. This gene-edited product provides a genetically heterogeneous loss-of-function model, enabling the study of AP3B1-dependent processes without clonal selection. The polyclonal format retains cellular diversity, allowing robust assessment of gene function across a population context.
The host cell line, HeLa, is a widely used immortalized human cervical adenocarcinoma cell line positive for human papillomavirus type 18 (HPV18). HeLa cells are a standard model in cell biology, known for rapid proliferation and adaptability to various experimental conditions. Their epithelial origin and HPV-driven transformation make them relevant for studying membrane trafficking in cancer contexts, as well as for general cell biology investigations.
AP3B1 encodes the beta-1 subunit of the heterotetrameric adaptor protein-3 (AP-3) complex, which functions in clathrin-dependent vesicular trafficking from endosomes to lysosomes and lysosome-related organelles. The AP-3 complex is recruited to donor membranes by ARF1 and interacts with cargo tails containing YXX? sorting motifs via its mu subunit, while the beta-1 subunit engages clathrin for coat assembly. Downstream targets include lysosomal membrane proteins LAMP1, LAMP2, and CD63, as well as tyrosinase in melanosomes. AP3B1 operates within a network involving interacting partners such as AP3D1, AP3S1, AP3M1, and sorting nexins, ensuring proper delivery of lysosomal hydrolases and membrane components.
In HeLa cells, disruption of AP3B1 impairs the trafficking of lysosomal membrane proteins, leading to their mislocalization to the plasma membrane or early endosomes, and potentially altering endolysosomal function. This mimics defects observed in Hermansky-Pudlak syndrome type 2, an autosomal recessive disorder characterized by oculocutaneous albinism, neutropenia, and platelet storage pool deficiency. The model is therefore instrumental for investigating the molecular pathology of lysosomal storage disorders and for dissecting the role of AP-3 in cellular homeostasis.
Researchers can employ these polyclonal knockout cells in a range of applications, including lysosomal storage disorder modeling, vesicle trafficking analysis, and cancer cell biology studies. Representative assays include Western blotting to verify AP3B1 loss, immunofluorescence for LAMP1 and CD63 colocalization, flow cytometry to quantify surface CD63 expression, and lysosomal enzyme activity measurements. Intracellular trafficking assays using pulse-chase and RNA-seq for lysosomal gene expression further expand the utility of this model in drug discovery for lysosomal diseases. For additional technical details or ordering information, please contact Ascent Research.
